findmyKOL

Jennifer Thorne, MD

Enriched profile

Chief, Division of Ocular Immunology; Cross Family Professor of Ophthalmology, Wilmer Eye Institute · Johns Hopkins School of Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Baltimore, MD · Northeast · United StatesSpecialtyOphthalmologyFocusDry Eye / Uveitis
Active KOLfindmyKOL type: EliteLatest publication2025Online presenceNone verifiedPayments2021–2025NIH funding2002–2007

Jennifer Thorne is Chief, Division of Ocular Immunology; Cross Family Professor of Ophthalmology, Wilmer Eye Institute at Johns Hopkins School of Medicine. OpenAlex indexes 435 publications with 17,495 citations (h-index 78); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.

Data verified 17 Oct 2026

Overview

Updated 18 Oct 2026

Jennifer Thorne, MD, is Chief, Division of Ocular Immunology at Johns Hopkins School of Medicine / Wilmer Eye Institute. The public record shows 435 publications with 17,495 citations (h-index 78), centered on Dry Eye / Uveitis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 7 companies, 2 NIH-funded awards (2002–2007).

  • Most recent indexed publication: 2025 · Cancers
  • Top research focus: Dry Eye / Uveitis
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Dry Eye / Uveitis1 trialUveitis1 trialUveitis, Posterior1 trialUveitis, Intermediate1 trial

Research focus

OpenAlex concept fingerprint
Dry Eye / Uveitis

Works with

trial sponsors and companies reporting payments
Gilead Sciences, Inc.Clinical trials—Industry payments14Merck Sharp & Dohme LLCClinical trials—Industry payments9Genentech USA, Inc.Clinical trials—Industry payments6Alcon Vision LLCClinical trials—Industry payments1BioCryst Pharmaceuticals, Inc.Clinical trials—Industry payments1F. Hoffmann-La Roche AGClinical trials—Industry payments1Johns Hopkins UniversityClinical trials1Industry payments—Sanofi Us Services Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
435publications

Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.

17,495citations

Total citations across indexed works.

78h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2002–2007

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 18 Oct 2026

7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    31.1%
    Prostaglandin Analog16.8%
    Latanoprost100%
    Part D<11 patients
    Corticosteroid14.3%
    Prednisolone Acetate100%
    Part D≥11 patients
  • Anti-infectives

    30.3%
    Macrolide20.2%
    Erythromycin100%
    Part D<11 patients
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.1%
    Valacyclovir100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    29.4%
    Corticosteroid29.4%
    Prednisone100%
    Part D≥12 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 18 Oct 2026

2 NIH research awards on record, funded 2002–2007 per NIH RePORTER. The latest:

Publications

Updated 18 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.